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Abstract 36 
In 2017, there were over 550,000 estimated new cases of multi-drug/rifampicin resistant 37 
tuberculosis (MDR/RR-TB), emphasizing a need for new treatment strategies.  Linezolid (LZD) 38 
is a potent antibiotic for antibiotic-resistant Gram-positive infections and is an effective treatment 39 
for TB.  However, extended LZD use can lead to LZD-associated host toxicities, most commonly 40 
bone marrow suppression.  LZD toxicities may be mediated by IL-1, a pathway important for 41 
early immunity during M. tuberculosis infection that later contributes to pathology.  We 42 
hypothesized LZD efficacy could be enhanced by modulation of IL-1 pathway to reduce BM 43 
toxicity and TB associated-inflammation.  We used two animal models of TB to test our 44 
hypothesis, mice and cynomolgus macaques. Antagonizing IL-1 in chronically-infected mice 45 
reduced lung neutrophil numbers and partially restored the erythroid progenitor populations that 46 
are depleted by LZD.  In macaques, we found no conclusive evidence of BM suppression 47 
associated with LZD, indicating our treatment time may have been short enough to avoid the 48 
toxicities observed in humans.  Though treatment was only 1 month, the majority of granulomas 49 
were sterilized with reduced inflammation (assessed by PET/CT) in animals treated with both 50 
LZD and IL-1 receptor antagonist (IL-1Rn).  However, overall lung inflammation was significantly 51 
reduced in macaques treated with both IL-1Rn and LZD, compared to LZD alone. Importantly, 52 
IL-1Rn administration did not noticeably impair the host response against Mtb or LZD efficacy in 53 
either animal model.  Together, our data support that inhibition of IL-1 in combination with LZD 54 
has potential to be an effective HDT for TB.  55 
 56 
Author summary 57 
 Host-directed therapies (HDTs) are a potential option in combating drug resistant TB as 58 
they can circumvent bacterial drug-resistance by targeting host responses rather than the 59 
pathogen.  Here we designed an HDT to target the IL-1 pathway, an inflammatory immune 60 
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response that is both critical and detrimental to TB disease outcome.  We combined IL-1Rn, an 61 
IL-1R antagonist, with linezolid (LZD) which is an effective antibiotic for drug-resistant M. 62 
tuberculosis.   Extended treatment causes severe host-toxicities that might be mediated in part 63 
by the IL-1 pathway. Our goals were to enhance LZD efficacy by negating LZD-host toxicities 64 
and to reduce adverse inflammation caused by TB.  In mice, IL-1Rn effectively reduced 65 
inflammatory signatures associated with TB and reversed linezolid-induced bone marrow 66 
suppression, the most common toxicity.  In cynomolgus macaques, inflammation, as assessed 67 
by PET/CT, was reduced by the combination of IL-1Rn and LZD therapy, compared to LZD 68 
alone.  In contrast to mice, we did not observe bone marrow suppression in macaques, 69 
highlighting the importance of both models when assessing prospective therapies.  These data 70 
show the potential of IL-1Rn as a therapy for TB and support LZD as an effective antibiotic 71 
against drug-resistant TB. 72 
 73 
Introduction 74 
Tuberculosis (TB) remains the top cause of death by a single infectious agent, with an 75 
estimated 10 million new active TB cases and 1.3 million deaths in 2017 alone (1).  Antibiotic 76 
treatment regimens are long and multi-drug resistant (MDR) and extensive-drug resistant (XDR) 77 
Mycobacterium tuberculosis (Mtb) strains have emerged, complicating treatment.  Even those 78 
patients that are cured of the infection can suffer permanent deficits in lung function that result 79 
from inflammation and fibrosis (2).  Host-directed therapies (HDTs) have been proposed as a 80 
potential option for improving therapy. Depending on the strategy, HDTs could enhance 81 
antimicrobial immune responses and shorten therapy, or inhibit pathological inflammation (3).  82 
Since HDT would be used as part of a multi-drug regimen, targeting mechanisms that increase 83 
drug exposure or decrease toxicity could also be envisioned.  While some HDT strategies hold 84 
promise, very few have been rigorously tested in pre-clinical models (4). 85 
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 86 
Interleukin-1 (IL-1) has been implicated in TB disease and inflammation, making it a possible 87 
target of HDT.  This cytokine plays an important yet complicated role in TB disease progression.  88 
The susceptibility of mice lacking critical mediators of IL-1 signaling indicates that some initial 89 
production of IL-1b upon Mtb infection is essential for priming downstream immune responses 90 
necessary for disease control (5-8).  In contrast, IL-1 is also responsible for the accumulation of 91 
disease-promoting neutrophils in chronically-infected susceptible mice, and genetic variants that 92 
result in higher IL-1b production are associated with increased disease severity and neutrophil 93 
accumulation in humans (9-11).  Given that HDT is designed to be administered to chronically-94 
infected patients during treatment, when persistent IL-1 production appears to play a more 95 
pathological role, it could be beneficial to block the inflammation and disease promoting 96 
activities of this cytokine.   97 
 98 
IL-1 may also play a role in the toxicity of linezolid (LZD), an increasingly important antibiotic for 99 
the treatment of drug-resistant TB, highlighted by its recent inclusion in a newly approved 100 
therapy for MDR-TB (12).  While LZD has shown efficacy against XDR and MDR TB, its wide-101 
spread use has been limited by severe host toxicities that occur after more than 4 weeks of 102 
treatment (13, 14).  Over the 6-20 month treatment course necessary to treat resistant TB, both 103 
reversible bone marrow suppression and irreversible neuropathies are common (15).  LZD-104 
associated toxicities are generally attributed to the inhibition of mitochondrial translation and 105 
LZD-mediated bone marrow suppression is promoted by the subsequent mitochondrial damage.  106 
This damage acts on the NOD-like receptor family, pyrin domain containing 3 (NLRP3) protein 107 
that has been shown to be necessary for LZD-mediated bone marrow suppression in mice (16).  108 
NLRP3, in conjunction with caspase-1 and ASC, forms an inflammasome complex, which 109 
cleaves a number of substrates resulting in cell death and/or the release of active of IL-1b.  110 
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While the importance of NLRP3 in bone marrow suppression is clear, the relative roles of 111 
inflammasome activation and IL-1 signaling remain uncertain.   112 
 113 
Based on these observations, inhibiting the IL-1 pathway by HDT could serve two purposes: 114 
first, to alleviate LZD-associated host toxicity, and second, to reduce the pathology associated 115 
with the IL-1 pathway during TB disease.  Due to the pro-inflammatory nature of the IL-1 116 
pathway, strict regulatory mechanisms exist within the host to quell this pathway.  IL-1 receptor 117 
antagonist (IL-1Rn) is a protein produced constitutively at low levels that can increase in 118 
response to a variety of cytokine signals.  IL-1Rn serves as a decoy ligand for the IL-1R1, 119 
blocking signal transduction and subduing activation of subsequent pro-inflammatory pathways 120 
(17).  Anakinra is an FDA-approved recombinant IL-1Rn that is used to treat rheumatoid 121 
arthritis.  As there are no FDA approved drugs to inhibit inflammasome activation, inhibition of 122 
the IL-1 pathway with biologics, such as Anakinra, is the only currently feasible strategy to 123 
modulate this pathway (18).  124 
 125 
We hypothesized that the combination of Anakinra (herein referred to as IL-1Rn) with LZD for 126 
treatment of active TB disease would reduce LZD-associated toxicities and host inflammation 127 
resulting in a more efficacious therapy.  To test this concept, we employed two established TB 128 
animal models to assess differing aspects of host responses to LZD and IL-1Rn.  We used 129 
multiple strains of mice to model distinct disease states and dissect the relative importance of 130 
the inflammasome and IL-1 signaling in HDT efficacy.  As a translational model, we used 131 
cynomolgus macaques in combination with [18F] FDG PET/CT serial imaging to track TB 132 
disease progression, including inflammation, before and during drug regimens (19).  133 
Cynomolgus macaques present with a similar spectrum of Mtb infection as humans, with 134 
pathology, including granuloma structure and diversity, that recapitulates human TB (20-22).  135 
Together, our data further verify LZD as an efficacious antibiotic in both mice and macaques 136 
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and indicate that addition of IL-1Rn may accelerate the resolution of inflammation and partially 137 
alleviate LZD-mediated BM suppression.   138 
 139 
Results 140 
IL-1 receptor blockade reduces inflammation in mouse models of TB disease.   141 
Given the complex role played by IL-1 during TB, we initially sought to determine the effect of 142 
inhibiting this cytokine during established TB disease in mice.  These studies compared two IL-1 143 
antagonists, a blocking antibody to the murine IL-1 receptor (aIL-1R1) and the human IL-1 144 
receptor antagonist, Anakinra (IL-1Rn), each delivered between days 14 and 28 post infection.  145 
Two mouse strains were employed to assess the effects of these treatments in animals with 146 
different amounts of IL-1 activity.  In relatively resistant C57BL/6 animals, mature IL-1 147 
production is controlled during chronic disease, whereas unregulated IL-1 drives inflammatory 148 
disease in Mtb-infected Nos2-/- mice (9, 10).   149 
 150 
While the human IL-1Rn had little effect in these models, the aIL-1R1 treatment significantly 151 
reduced PMN numbers in the lungs of both resistant and susceptible mouse strains, and 152 
reversed the weight loss observed in Nos2-/- mice (Fig. 1A-B).  While neither regimen 153 
significantly altered the lung bacterial burden, both IL-1Rn and aIL-1R1 treatment reduced 154 
bacterial burden in the spleens of Nos2-/- mice (Fig. 1C-D).  This generally beneficial effect of 155 
aIL-1R1 treatment was consistent with qualitatively improved histopathological disease (Fig. 156 
1E).  By no metric did aIL-1R1 treatment exacerbate established disease in either mouse strain. 157 
 158 
IL-1 blockade alleviates lung inflammation and hematopoietic suppression during 159 
LZD treatment in mice.  160 
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The IL-1R1 blocking antibody aIL-1R1 was next tested in combination with LZD to determine 161 
whether the efficacy or toxicity of the antibiotic was altered.  C3HeB/FeJ mice, which are 162 
relatively susceptible to Mtb and develop histopathological lesions that more closely resemble 163 
human disease, were used for these studies.  Mice with established disease were treated 164 
between days 28 and 46 post-infection with vehicle alone, LZD, aIL-1R1 or a combination of the 165 
two.  As previously reported, LZD was effective in this model, reducing lung neutrophil numbers, 166 
bacterial burden and weight loss (Fig. 2 A-D) (23).  The addition of aIL-1R1 to this regimen 167 
further reduced lung neutrophil numbers, and did not significantly alter the antimicrobial activity 168 
of LZD.  As IL-1b production in response to both Mtb infection and LZD treatment depends 169 
largely on the NLRP3 inflammasome, we also investigated a regimen in which LZD and a small 170 
molecule NLRP3 inhibitor (MCC950) was administered between days 56 and 77 post-infection.  171 
As observed with aIL-1R1, the addition of MCC950 reduced PMN numbers in the lung, relative 172 
to LZD alone, and did not significantly alter the rate of bacterial killing (Fig. 2 E-G).  Using a 173 
more rapid treatment protocol and C57BL/6 mice with genetic deficiencies in Caspase 1 or 174 
NLRP3, we confirmed that the antimicrobial activity of LZD was unaffected by inflammasome 175 
activation (Supplementary Fig. 1).  Mice were treated between days 14 and 28 post-infection 176 
and the effect of LZD on bacterial burden and lung neutrophil number was at least as large in 177 
the knockout animals as the wild type controls.   178 
 179 
Hematopoietic suppression was assayed in bone marrow and spleens of C3HeB/FeJ mice.  180 
Both organs are significant sites for hematopoiesis in small animals, in which the bone marrow 181 
has insufficient capacity, particularly when the requirement for blood cells increases.  Using flow 182 
cytometry, erythroid progenitors can be divided into a progression of precursors; pro-erythrocyte 183 
(ProE), EryA, EryB, and EryC (Fig. 3A).  These populations were quantified in each tissue of 184 
Mtb-infected animals treated with LZD and/or aIL-1R1.  In both bone marrow and spleen, LZD 185 
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had a profound effect, nearly eliminating early erythroid progenitors of the ProE, EryA and EryB 186 
classes (Fig. 3B-E).  Simultaneous treatment with aIL-1R1 largely reversed the effect of LZD in 187 
the spleen, restoring these immature precursors to approximately half of their untreated levels.  188 
While aIL-1R1 also significantly increased the number of erythroid precursors in the BM, the 189 
suppression of LZD toxicity was less pronounced at this site.   190 
 191 
In sum, studies in the mouse model indicated that the addition of aIL-1R1 to an LZD regimen 192 
could reduce the number of lungs PMN and ameliorate hematopoietic toxicity, while not 193 
compromising antimicrobial activity.  These observations justified further studies in a non-human 194 
primate model. 195 
 196 
Changes in TB disease in macaques treated with LZD and HDT by PET/CT  197 
Previously we published the efficacy and pharmacokinetics of LZD in cynomolgus macaques 198 
treated for 8 weeks with a single daily dose of 30 mg/kg (14).  To adhere to FDA guidelines for 199 
LZD administration at the time we initiated this study, and reproduce clinical exposure at 600 mg 200 
twice daily (b.i.d.), we shortened treatment duration to 4 weeks and increased the dosing 201 
frequency to 30 mg/kg b.i.d.  Dose finding studies were carried out in uninfected cynomolgus 202 
macaques to ensure that adequate drug concentrations similar to those achieved in patients at 203 
600 mg b.i.d. were reached in the blood (Supplementary Fig. 2A).     204 
 205 
To assess this HDT/LZD regimen, we infected 10 cynomolgus macaques with Mtb strain 206 
Erdman (12 CFU via bronchoscope) and monitored development of active TB disease (~3-5 207 
months) (Supplementary Table 1 and Supplementary Fig. 2B).  The macaques were then 208 
randomized to a 4-week drug regimen of LZD (n=5) or LZD+IL-1Rn (n=5) (Supplementary Fig. 209 
2B).  One advantage of this model is the ability to track disease progression throughout infection 210 
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and treatment using serial 18F-FDG PET CT scans (14, 24). Lung inflammation was quantified 211 
by total FDG activity in the lungs before and during treatment (Fig. 4A-B and Supplementary 212 
Table 1)(19).  In LZD treated macaques, there was no significant decrease in total lung FDG 213 
activity after 4 weeks (p=0.2876), although there was a trend for an initial reduction in 214 
inflammation after 2 weeks of treatment (p=0.0857)(Fig. 4B).  In contrast, LZD+IL-1Rn treatment 215 
resulted in a significant reduction in total lung FDG activity after 2 and 4 weeks (p=0.0242, 216 
p=0.0237 respectively).  We assessed changes in granulomas during treatment by measuring 217 
physical size (CT) and metabolic activity (measured as the standard uptake value of FDG per 218 
granuloma, SUVR) (Fig. 4C-D)(19).  During treatment, the majority of granulomas decreased in 219 
size with no differences between LZD and LZD+IL1-Rn treated animals.  However, granuloma 220 
metabolic activity (SUVR) was significantly reduced in LZD+IL-1Rn treated macaques 221 
compared to those treated with LZD alone for all granulomas.  These data indicate that blocking 222 
of IL-1R in combination with LZD reduces inflammation in whole lungs and individual 223 
granulomas more effectively than LZD treatment alone.   224 
 225 
Supplementary Table 1.  List of macaques for study and PET/hot values 226 
 227 
Provided are details regarding macaques utilized for this study.  DPI = days post infection. 228 
 229 
Addition of IL-1Rn does not significantly reduce bacterial burden 230 
HDT Study
NHP Age (yr) Gender Infection Dose Treatment Group DPI at Treatment Start Days of Treatment DPI at Necropsy Necropsy Score Total CFU PreTx PEThot 2wk PEThot 4wk PEThot
29716 5.9 F 12 CFU LZD 117 28 145 24 61839 526777.88 58333.57 35664.45
29816 7.1 F 12 CFU LZD 110 28 138 45 4445 11003.65 1309.29 531.02
30016 7 F 12 CFU LZD 103 29 132 31 1413 85068.79 123759.67 28665.24
30216 7.1 F 12 CFU LZD 138 31 169 32 1090 2113.02 401.05 3884.92
30316 7.1 F 12 CFU LZD 117 30 147 37 8005 1453.44 562.79 1828.43
18816 10.9 M 12 CFU LZD+IL-1Rn 117 30 147 26 505 3236.21 673.86 1520.78
19116 7.2 M 12 CFU LZD+IL-1Rn 117 28 145 25 330 3304.52 1469.77 1562.60
19416 9.9 M 12 CFU LZD+IL-1Rn 138 30 168 10 727 872.50 73.54 73.30
20416 8.2 M 12 CFU LZD+IL-1Rn 110 31 141 28 1260 26957.57 10456.67 2802.92
30116 6.4 F 12 CFU LZD+IL-1Rn 103 31 134 67 20905 110837.75 48461.60 7609.82
Historical Controls*
NHP Age (yr) Gender Infection Dose DPI at Necropsy Necropsy Score Total CFU
18214 8.3 M 39 CFU 84 50 2935647
18314 8.3 M 39 CFU 91 84 1319857
1514 6.2 M 38 CFU 118 56 112433
*PET/CT data previously reported in PMID: 28592427
Supplemental Table 1 - Macaque Study Data
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While IL-1Rn should not have direct bactericidal activity, this agent could still influence the 231 
expression of anti-bacterial immunity. This effect could be beneficial if immune responses are 232 
enhanced, or detrimental if IL-1 is necessary for host killing of bacteria.  Therefore, we 233 
performed comprehensive bacterial burden analysis at necropsy, by identifying the majority of 234 
granulomas and other TB pathologies on PET CT scans, obtaining each individually at necropsy 235 
and culturing all lesions, thoracic lymph nodes, and uninvolved lung tissue separately, as well 236 
as extrapulmonary lesions, as previously described (20).  Total thoracic CFU (lung + lymph 237 
nodes) was not significantly different between LZD and LZD + IL-1Rn macaques (p = 0.1508) 238 
(Fig. 5A), with similar frequencies of sterilized granulomas (LZD = 68.42%, LZD+IL-1Rn = 239 
72.22%). In the current study, we did not have untreated control macaques, so we provide total 240 
thoracic CFU for 3 similarly infected historical controls (untreated) for reference; these data 241 
were excluded from statistical analyses. This supports that high dose LZD as a single drug is 242 
effective at killing bacteria even in a short (4 week) regimen. Bacterial burden in CFU+ thoracic 243 
lymph nodes was similar between the groups though trended towards lower CFU in LZD+IL-244 
1Rn treated macaques (p=0.0965) (Fig 5B).  We previously reported that a 2-month lower dose 245 
regimen of LZD could reduce bacterial burden compared to untreated controls, with ~80% 246 
sterilized granulomas (14). Since the bacterial burden in macaques with active TB can vary 247 
substantially, we estimated the pre-treatment total thoracic CFU from the total lung FDG by PET 248 
CT as previously described (20), and compared the actual bacterial burden post-treatment 249 
against the estimated pre-treatment value.  All macaques, regardless of treatment group, had 250 
lower total thoracic CFU at necropsy compared to the estimated total thoracic CFU prior to 251 
treatment initiation (Fig. 5C).  Our data indicate that while IL-1Rn did not significantly enhance 252 
bacterial killing, it did not impair LZD-mediated bacterial clearance.   253 
 254 
Lack of LZD-induced bone marrow suppression in macaques 255 
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In humans, LZD is associated with host toxicities during extended treatment periods of > 4 256 
weeks (25).  To determine whether bone marrow suppression occurred during the 4-week high 257 
dose LZD therapy and whether IL-1Rn could modulate observable host toxicities, we isolated 258 
bone marrow at necropsy from the sternum of each macaque and assessed erythropoietic 259 
progenitor populations and mitochondrial function by flow cytometry (Fig. 6A).  During 260 
homeostatic erythropoiesis, a 1:8 ratio is maintained between ProE and EryC populations, 261 
which can be used to indicate disruption to erythropoiesis.  There was no significant difference 262 
in ProE:EryC ratios between the treatment groups or compared to untreated macaques with Mtb 263 
infection (Fig. 6B).  However, none of the macaque groups had a homeostatic ratio regardless 264 
of treatment.  These data indicate that Mtb infection or TB disease alone may disrupt bone 265 
marrow homeostasis.  To determine whether LZD was affecting bone marrow mitochondrial 266 
function, we stained cells with MitoTrackerTM Red CMXRos that only stains mitochondria with 267 
active membrane potential, indicating function of those organelles (Fig. 6B).  Regardless of 268 
treatment, the MitoTracker MFI remained similar, indicating that mitochondrial function is the 269 
same among groups.  To confirm our observations, a pathologist evaluated bone marrow tissue 270 
sections and found no observable differences between TB only, LZD and LZD+IL-1Rn groups in 271 
terms of cellularity (myeloid:erythroid ratios) or abnormalities (Fig. 6C).  While we could not 272 
consistently identify progenitor populations in blood or spleen, we performed complete blood 273 
counts (CBCs) during treatment to identify signs of bone marrow suppression (i.e., anemia, 274 
thrombocytopenia). There were no differences between LZD and LZD+IL-1Rn treatments 275 
(Supplementary Fig. 3).  In conclusion, 4 weeks of LZD was not sufficient to induce observable 276 
bone marrow suppression in cynomolgus macaques and blocking of IL-1R did not alter bone 277 
marrow status during LZD treatment of TB.   278 
 279 
Reduction in inflammatory signatures in the lung after HDT 280 
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To determine whether IL-1Rn modulated immune populations in the airway of the lung during 281 
treatment, bronchoalveolar lavages (BAL) were acquired prior to the start of treatment and 3 282 
weeks post treatment.  Innate and adaptive immune cell populations were identified and 283 
frequencies were assessed by flow cytometry (Fig. 7A).  Frequencies of CD4 and CD8 T cells 284 
(CD3+, CD8+ or CD4+) in BAL remained stable and similar in both groups.  Although 285 
macrophage (CD11b+CD206+) populations were relatively unchanged, there was a significant 286 
reduction in neutrophil (CD11b+, Calprotectin+) frequency in the BAL after 3 weeks of treatment 287 
(pooled groups) (p=0.0098).  This observation was similar to that observed in mice (Fig 2A).  To 288 
determine whether the cytokine milieu in the airways changed during treatment, a subset of 3 289 
animals per group were chosen at random for analysis by multi-plex using 10X concentrated 290 
BAL fluid (Fig. 7B).  Given the small subset, statistical analysis was performed on combined 291 
treatment groups to only compare pre and post treatment changes.  We assessed IL-1b and IL-292 
1RA as IL-1Rn may modulate this pathway and saw no significant changes after treatment (IL-293 
1b p=0.1562, IL-1RA p=0.1250).  Interferon-inducible T cell alpha chemoattractant (I-TAC) is 294 
upregulated in response in interferons and IL-1 and is generally an indicator of inflammation, 295 
which also trended towards reduced levels post treatment, however was not statistically 296 
significant (p=0.0625). IL-8, a neutrophil chemoattractant, was significantly reduced after 297 
treatment, mirroring the reduction in neutrophil frequency observed by flow cytometry and 298 
mouse data.  These data suggest that treatment with either LZD or LZD+IL-1Rn rapidly reduces 299 
inflammatory signatures associated with TB disease in the airways. 300 
 301 
IL-1 blockade modulates granuloma specific responses and healing dynamics 302 
To determine whether IL-1Rn modulated immune responses at the site of infection, we chose at 303 
random 5 granulomas per animal (25 per treatment group) and performed a multi-plex analysis 304 
of granuloma supernatants (Fig. 8A).  There were no significant differences in IL-1b, IL-1RA, or 305 
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IL-18 levels, which are associated with the IL-1 pathway.  IL-2 and IL-17 are correlated with 306 
protective immune responses during TB (26); there was a trend for higher IL-2 levels in LZD+IL-307 
1Rn treatment and a statistically significant increase in IL-17a in LZD+IL-1Rn treated animals.  308 
G-CSF/CSF-3 levels were significantly higher in LZD+IL-1Rn treated granulomas, providing 309 
further evidence of IL-1Rn immune modulation.  The IL-1 pathway is associated with fibrosis, 310 
which increases in granulomas during drug treatment. IL-17 and G-CSF are also associated 311 
with fibrosis (27).  Granulomas suitable for histological analysis were evaluated by a blinded 312 
pathologist and lesions were categorized based on treatment groups and descriptive qualities 313 
(Fig. 8B).  Of lesions acquired from LZD only animals, 71.43% were deemed fibrotic (n= 40/56), 314 
while those with the addition of IL-1Rn had 84.78% fibrotic lesions (n=39/46) with no significant 315 
difference in frequency of fibrotic lesions between treatment groups.  We also compared the 316 
number and frequency of granulomas that were deemed necrotizing or non-necrotizing (“other” 317 
indicates neither categorization).  Granulomas from LZD+IL-1Rn treated animals had 318 
significantly more non-necrotizing granulomas (73.91%, n=34/46), compared to those from LZD 319 
alone treated macaques (46.43%, n=26/56).  The proportion of necrotizing granulomas was 320 
significantly lower in the LZD+IL-1Rn treatment group (13.04%, n=6/56) compared to LZD alone 321 
(30.36%, n=17/56) (p=0.0151).  These data suggest that addition of IL-1Rn may influence 322 
antibiotic-associated healing dynamics of granulomas. 323 
 324 
Discussion 325 
HDTs are a tantalizing solution in combating drug-resistant pathogens, however the 326 
complexities of host-pathogen interactions and host variability call for rigorous pre-327 
clinical testing before implementation in humans.  Here, we sought to determine the 328 
efficacy and safety of an HDT for TB comprised of LZD and IL-1Rn.  IL-1 has a complex 329 
role during TB, as IL-1 is important for early control of infection, yet damaging in later 330 
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stages of disease.  To validate the safety of IL-1Rn in this context, we first assessed the 331 
effects of IL-1Rn on TB disease progression in mice.  Using aIL-1R1 blockade, 332 
antagonism of IL-1R1 did not exacerbate disease and reduced PMN infiltrates which are 333 
associated with pathological inflammation. While inhibition of IL-1 signaling during the 334 
early stages of infection has been shown to potentiate disease, the beneficial effect of 335 
IL-1 inhibition that we observed in multiple mouse models of TB highlights the generally 336 
pathological role for this cytokine during established infections (7, 8).   337 
When co-administered with LZD, blockade of IL-1R1 reduced PMN infiltrates in the 338 
mouse models, compared to the antibiotic alone.  Similarly, IL-1Rn reduced 339 
inflammation in the granulomas of macaques, as well as overall lung inflammation as 340 
assessed by PET CT, but did not significantly enhance bacterial clearance.  A trend of 341 
lower CFU in CFU+ lymph nodes (p=0.0965) was observed from macaques treated with 342 
LZD+IL-1Rn compared to LZD alone.  We hypothesize that IL-1Rn may reduce 343 
inflammation in tissues to allow for enhanced penetration of LZD to reduce bacterial 344 
burden in tissues.  Given that lymph nodes are a site of Mtb persistence, this finding is 345 
worth further exploration as a means of potentially enhancing drug penetration in 346 
tissues (28).   347 
 348 
In the BAL, we observed a decrease in neutrophils (PMNs) during HDT and a 349 
corresponding decrease in IL-8 in both treatment group (LZD or LZD+IL-1Rn), indicating 350 
LZD alone was efficacious in reducing PMN inflammatory signatures, likely due to the 351 
reduction in bacterial burden.  In granulomas, levels of IL-1b, IL-1RA and IL-18 were not 352 
affected by IL-1Rn treatment in the subset examined.  As IL-1Rn does not affect 353 
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inflammasome formation and function, only IL-1R1 signal transduction, it is not 354 
surprising that IL-1b and IL-18 production were not affected by IL-1Rn.  Of the 30 355 
cytokines and chemokines assessed, IL-2, IL-17A and G-CSF were the most modulated 356 
after IL-1Rn treatment.  IL-2 and IL-17A have protective functions during TB and are 357 
primarily expressed by T cells (26).  While IL-1b has been reported to enhance IL-17A 358 
production by T cells in mice, these studies primarily have utilized model-antigen 359 
systems while our study reflects a chronic infection model (29).  IL-1 is known to be 360 
protective early during Mtb infection while exacerbating pathology during later infection, 361 
highlighting that the effects of IL-1 on adaptive immunity are complex and likely 362 
dependent on the host and infection model.  G-CSF was increased in granulomas from 363 
LZD+IL-1Rn treated macaques which, combined with our observations of reduced PMN 364 
infiltrates in mouse lungs and macaque airways, indicated a paradoxical role of G-CSF 365 
as a neutrophil production and differentiation factor (30).   However, in a model of LPS-366 
induced lung injury it was shown that G-CSF blockade induced accumulation of PMNs 367 
and increased inflammation in the lungs, indicating pulmonary inflammation may not 368 
follow dogmatic rules of canonical inflammatory pathways (30).    369 
 370 
Fibrosis is modulated by the IL-1 pathway, however while fibrosis is associated with 371 
granuloma healing, lung fibrosis can cause secondary complications after TB disease 372 
resolution (2) .  We have shown in previous studies that drug therapy for TB induces 373 
fibrotic healing in granulomas (31, 32). Therefore, we assessed whether IL-1Rn was 374 
associated with changes in granuloma pathology.  While we did not observe a 375 
significant difference in the frequency of fibrotic versus non-fibrotic granulomas 376 
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(p=0.1531), there was a significant decrease in necrotizing granulomas when IL-1Rn 377 
was added to LZD therapy.  Thus, although there is no synergistic effect between IL-378 
1Rn and LZD in promoting fibrosis associated with drug clearance, the reduction in 379 
neutrophils could skew granuloma resolution towards a non-necrotizing, fibrotic lesion.   380 
 381 
We also assessed LZD-associated bone marrow suppression and reversal with IL-1Rn 382 
therapy.  We designed our HDT to match the current FDA guidelines for LZD and IL-383 
1Rn schedules, which resulted in a lack of observable bone marrow suppression in 384 
macaques.  In mice however, LZD-induced bone marrow suppression was reduced with 385 
the addition of IL-1R1 antagonists, supporting our initial hypothesis. The role of IL-1 386 
signaling is consistent with the ability of IL-1 to suppress erythropoiesis in mice by 387 
reducing the number of progenitors (33).  The remaining deficit in erythropoiesis during 388 
IL-1 blockade could reflect either incomplete inhibition by IL-1Rn or an independent role 389 
of inflammasome activation.  Optimizing this effect will require further work to 390 
understand the relative roles of IL-1 signaling and inflammasome activation.  391 
  392 
Our data support and extend our previous data in macaques that LZD has excellent 393 
efficacy against TB, even as a single-drug given for only 4-weeks, providing additional 394 
support for LZD as an antimicrobial for MDR/XDR-TB cases (12).  IL-1Rn therapy in 395 
conjunction with LZD was successful in reducing TB-associated inflammation with no 396 
negative effects on Mtb clearance, however additional studies addressing long-term 397 
effects on immune responses and TB disease resolution are needed.  Anakinra (IL-1Rn) 398 
is already FDA-approved for adult and pediatric use in other inflammatory disorders; our 399 
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data provide pre-clinical evidence that IL-1Rn could be a potential therapy for cases of 400 
severe TB to quell excessive inflammation and improve standard therapies.  Our study 401 
highlights the potential of HDTs for TB but also the necessity of assessment in 402 
translational models prior to implementation in human trials. 403 
 404 
Methods 405 
Ethics Statement 406 
All experimental manipulations, protocols, and care of the animals were approved by 407 
the University of Pittsburgh School of Medicine Institutional Animal Care and Use 408 
Committee (IACUC). The protocol assurance number for our IACUC is A3187-01. Our 409 
specific protocol approval numbers for this project are 15117082, 16017370, 18124275, 410 
13011368 and 16027525.  The IACUC adheres to national guidelines established in the 411 
Animal Welfare Act (7 U.S.C. Sections 2131 - 2159) and the Guide for the Care and 412 
Use of Laboratory Animals (8th Edition) as mandated by the U.S. Public Health Service 413 
Policy. 414 
All macaques used in this study were housed at the University of Pittsburgh in rooms 415 
with autonomously controlled temperature, humidity, and lighting. Animals were singly 416 
housed in caging at least 2 square meters that allowed visual and tactile contact with 417 
neighboring conspecifics. The macaques were fed twice daily with biscuits formulated 418 
for nonhuman primates, supplemented at least 4 days/week with large pieces of fresh 419 
fruits or vegetables. Animals had access to water ad libitem. Because our macaques 420 
were singly housed due to the infectious nature of these studies, an enhanced 421 
enrichment plan was designed and overseen by our nonhuman primate enrichment 422 
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specialist. This plan has three components. First, species-specific behaviors are 423 
encouraged. All animals have access to toys and other manipulata, some of which will 424 
be filled with food treats (e.g. frozen fruit, peanut butter, etc.). These are rotated on a 425 
regular basis. Puzzle feeders foraging boards, and cardboard tubes containing small 426 
food items also are placed in the cage to stimulate foraging behaviors. Adjustable 427 
mirrors accessible to the animals stimulate interaction between animals. Second, 428 
routine interaction between humans and macaques are encouraged. These interactions 429 
occur daily and consist mainly of small food objects offered as enrichment and adhere 430 
to established safety protocols. Animal caretakers are encouraged to interact with the 431 
animals (by talking or with facial expressions) while performing tasks in the housing 432 
area. Routine procedures (e.g. feeding, cage cleaning, etc) are done on a strict 433 
schedule to allow the animals to acclimate to a routine daily schedule. Third, all 434 
macaques are provided with a variety of visual and auditory stimulation. Housing areas 435 
contain either radios or TV/video equipment that play cartoons or other formats 436 
designed for children for at least 3 hours each day. The videos and radios are rotated 437 
between animal rooms so that the same enrichment is not played repetitively for the 438 
same group of animals. 439 
 All animals are checked at least twice daily to assess appetite, attitude, activity 440 
level, hydration status, etc. Following M. tuberculosis infection, the animals are 441 
monitored closely for evidence of disease (e.g., anorexia, weight loss, tachypnea, 442 
dyspnea, coughing). Physical exams, including weights, are performed on a regular 443 
basis. Animals are sedated prior to all veterinary procedures (e.g. blood draws, etc.) 444 
using ketamine or other approved drugs. Regular PET/CT imaging is conducted on 445 
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most of our macaques following infection and has proved very useful for monitoring 446 
disease progression. Our veterinary technicians monitor animals especially closely for 447 
any signs of pain or distress.  If any are noted, appropriate supportive care (e.g. dietary 448 
supplementation, rehydration) and clinical treatments (analgesics) are given. Any 449 
animal considered to have advanced disease or intractable pain or distress from any 450 




Mice, infection and treatment 455 
C57BL/6 (stock no. 000664), Nos2-/- (B6.129P2-Nos2tm1Lau/J, stock no. 002609), C3HeB/FeJ 456 
(stock no. 00658), and Nlrp3-/- (B6.129S6-Nlrp3tm1Bhk/J, stock no. 021302) were purchased from 457 
the Jackson Laboratory. Breeding pairs of Caspase-1/11 double knock out mice were kindly 458 
provided by Prof. Katherine Fitzgerald of the Department of Infectious Diseases at University of 459 
Massachusetts (UMASS) Medical School and bred in house. Mice were housed under specific 460 
pathogen-free conditions, and in accordance with the UMASS Medical School, IACUC guidelines. 461 
All mouse strains used in this study were of C57BL/6 background unless otherwise indicated. 462 
 463 
The wild type strain of M. tuberculosis (Mtb) Erdman was used in these studies.  Bacteria were 464 
cultured in 7H9 medium containing 0.05% Tween 80 and OADC enrichment (Becton Dickinson). 465 
For infections, mycobacteria were suspended in phosphate-buffered saline (PBS)-Tween 80 466 
(0.05%); clumps were dissociated by sonication, and ~100 CFU were delivered via the respiratory 467 
route using an aerosol generation device (Glas-Col, Terre Haute, IN). At indicated time points 468 
mice were treated with 200mg/kg of Linezolid (LZD). These drugs were prepared in 0.5% 469 
carboxymethyl cellulose (CMC) and Polyethylene glycol 300 solution as the vehicle. Cohorts of 470 
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mice were treated with anti-IL-1R1 antibody (InVivoMab, anti-mouse IL-1R, Clone JAMA147, 471 
BioXcell), or human recombinant IL-1 receptor antagonist (IL-1Rn, KineretTM) either alone or in 472 
combination with LZD. 0.5% CMC and Polyethylene glycol was used as vehicle control. All 473 
antibiotic treatment was done by daily oral gavage. Anti-IL-1R1 (100ug/mouse/0.2mL) was 474 
administered every alternate day by subcutaneous and intraperitoneal route. IL-1Rn (Kineret) was 475 
administered (25mg/kg/mouse) everyday by subcutaneous route. 476 
 477 
Macaque pharmacokinetic study and analytical method.  478 
Uninfected macaques designated for other studies (n=3) were given 20mg/kg or 40mg/kg by oral 479 
gavage and plasma acquired at 0, 5, 19, 15, 20, 25 and 30 hours post LZD administration.  High 480 
pressure liquid chromatography coupled to tandem mass spectrometry (LC/MS-MS) analysis was 481 
performed on a Sciex Applied Biosystems Qtrap 4000 triple-quadrupole mass spectrometer 482 
coupled to an Agilent 1260 HPLC system to quantify LZD in macaque plasma. LZD 483 
chromatography was performed on an Agilent Zorbax SB-C8 column (2.1x30 mm; particle size, 484 
3.5 µm) using a reverse phase gradient elution.  Milli-Q deionized water with 0.1% formic acid 485 
was used for the aqueous mobile phase and 0.1% formic acid in acetonitrile for the organic mobile 486 
phase. Multiple-reaction monitoring (MRM) of parent/daughter transitions in electrospray positive-487 
ionization mode was used to quantify the analytes.  Sample analysis was accepted if the 488 
concentrations of the quality control samples were within 20% of the nominal concentration.  Data 489 
processing was performed using Analyst software (version 1.6.2; Applied Biosystems Sciex). 490 
Neat 1 mg/mL DMSO stocks for all compounds were serial diluted in 50/50 Acetonitrile water to 491 
create standard curves and quality control spiking solutions. 20 µL of neat spiking solutions were 492 
added to 20 µL of drug free plasma or control tissue homogenate, and extraction was performed 493 
by adding 180 µL of Acetonitrile/Methanol 50/50 protein precipitation solvent containing the 494 
internal standard (10 ng/mL verapamil & deuterated LZD-d3).  Extracts were vortexed for 5 495 
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minutes and centrifuged at 4000 RPM for 5 minutes.  100 µL or supernatant was transferred for 496 
LC-MS/MS analysis and diluted with 100 µL of Milli-Q deionized water.  497 
Rhesus macaque plasma (Lithium Heparin, Bioreclamation IVT, NY) was used as a surrogate to 498 
cynomolgus macaque plasma to build standard curves. LZD-d3 internal standard and verapamil 499 
were purchased from Toronto Research Chemical. The lower and upper limits of quantitation 500 
(LLOQ and ULOQ) were 1 ng/mL and 50,000 ng/mL respectively.  The following MRM transitions 501 
were used for LZD (338.00/235.00), LZD-d3(341.20/297.20), and verapamil (455.40/165.20). 502 
 503 
Macaques, infection and treatment 504 
All housing, care, and experimental procedures were approved by the University of Pittsburgh 505 
School of Medicine Institutional Animal Care and Use Committee (IACUC). Examination of 506 
animals was performed in quarantine to assess physical health and confirmation of no previous 507 
M. tuberculosis infections as previously described (34).  Cynomolgus macaques (Macaca 508 
fascicularis) (N=10) were purchased for this study from (Valley Biosystems).  Bone marrow 509 
control (non-drug treated) samples were taken from Mtb-infected cynomolgus macaques in 510 
unrelated ongoing studies (N=5). For the current study, all 10 animals were infected 511 
bronchoscopically with 12 CFU of Mtb strain Erdman.  After active disease developed (3-5 512 
months), NHPs were randomized to LZD only (N=5) or LZD+IL-1Rn (N=5) treatment groups. For 513 
randomization, macaques were paired based on total FDG activity in lungs (a surrogate for total 514 
thoracic CFU), and then assigned to treatment by coin flip (20). LZD was administered twice a 515 
day orally with food (30mg/kg), while IL1-Rn was given at 2mg/kg once each day by 516 
subcutaneous injection.  All animal data are provided in Supplementary Table 1. Medication 517 
compliancy was monitored at every administration and pharmacokinetic analysis performed at 518 
select times.  Drug treatments were administered for 4 weeks prior to necropsy.  519 
Bronchoalveolar lavages (BAL) were performed prior to drug-treatment and 3 weeks-post start 520 
of treatment for CFU, flow cytometry and multiplex assays. 521 
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 522 
Macaque PET/CT Imaging 523 
Positron emission tomography (PET) with computed tomography (CT) imaging was performed 524 
with 2-deoxy-2-[18F]-D-deoxyglucose (FDG) throughout the study as previously described (19).  525 
Serial scans were performed throughout the study to track disease progression and changes 526 
during drug treatment.  Total FDG activity of the lungs was measured over the course of 527 
infection and drug treatment as previously described (19).  Granulomas identified on scans were 528 
denoted, measured (mm) and standard uptake values (SUVR) were determined to assess 529 
metabolic activity, a readout for inflammation.  SUVR values were normalized to muscle and 530 
SUVR and size measurements were determined at each scan over time to compare pre-and 531 
post-drug treatment.  Each animal was scanned prior to necropsy to identify granulomas for 532 
matching at necropsy; granulomas > 1mm are distinguishable by PET/CT.   533 
 534 
Macaque Necropsy 535 
Necropsies were performed as previously described.  In short, multiple tissues (granulomas, lung 536 
lobes, thoracic lymph nodes, peripheral lymph nodes, liver, spleen, bone marrow) were excised 537 
and homogenized into single-cell suspensions for assessment of bacterial burden and 538 
immunological assays.  Granulomas were individually excised (PET/CT identified and others not 539 
identified on scans) and split (size permitting) with one-half for homogenization and single cell 540 
suspension and the other half processed for histological analysis.   Bone marrow samples were 541 
obtained from the sternum, with a portion sent for histological analysis while single cell 542 
suspensions were acquired as previously described (35). Bacterial burden was assessed from 543 
each tissue by plating serial dilutions on 7H11 agar plates and incubated at 37°C in 5% CO2 for 544 
21 days before enumeration of Mtb CFU. 545 
 546 
Flow cytometry and Immunoassays 547 
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Mice.  Single cell suspensions were prepared from the infected mouse organs. Briefly, lung tissue 548 
was digested with Collagenase type IV/DNaseI and passed through 40 µm cell strainers to obtain 549 
single cell suspension. Red blood cells were lysed using Tris-buffered Ammonium Chloride (ACT) 550 
Non-specific antibody binding sites were blocked by Fc-Block CD16/32 (Clone 93, cat. no. 551 
101319) and the cells were stained with anti-CD3-PE (Clone 17A2, cat. no. 100205), anti-CD11b-552 
PerCP Cy5.5 (Clone M1/70, cat. no.101227), anti-Ly-6G-FITC (Clone 1A8, cat. no.127605), anti-553 
Ly-6C-PE (Clone HK1.4, cat. no.128007), anti-Gr1-APC (Clone RB6-8C5, cat. no.108411), anti-554 
Ter119-PE (Clone TER119, cat. no.116208), anti-CD71-FITC (clone RI7217, cat. no. 113806). 555 
Antibodies were purchased from BioLegend. All analyses were performed on live cells only after 556 
staining them with fixable live dead stain conjugated with eFlour780, purchased from 557 
eBiosciences. All the staining was done according to the manufacturer’s instructions. Lung, 558 
spleen and bone marrow cells were surface stained for 30 minutes at room temperature, fixed for 559 
20 minutes at 40C using the Cytofix buffer (BD-Biosciences, cat. no. 554655). Data were acquired 560 
in a BD LSRII flow cytometer in the flow cytometry core facility at UMASS medical school and 561 
analyzed with FlowJo Software (Treestar, Inc.).  Gating strategies are provided in applicable 562 
figures. 563 
Macaques.  Single cell suspensions acquired from homogenization of granulomas, lung lobes 564 
and lymph nodes were subjected to intracellular cytokine staining (ICS).  Prior to staining, cells 565 
were incubated in RPMI 1640 containing 1% HEPES, 1% L-glutamine, 10% human AB serum, 566 
and 0.1% brefeldin A (Golgiplug; BD Biosciences) for 3 h at 37°C in 5% CO2.  After viability 567 
staining (Invitrogen), surface antigens and intracellular cytokines were assessed using standard 568 
protocols.  Surface markers include CD3 (SP34-2; BD Pharmingen), CD4 (L200; BD Horizon), 569 
CD8 (RPA-T8; BD Horizon) for T cells and CD11b (ICRF44; BD Pharmingen), CD206 (19.2; BE 570 
Pharmingen) for macrophages/neutrophils.  Calprotectin (27E10; ThermoFisher) was stained 571 
intracellularly to identify neutrophils.  For bone marrow, single cell suspensions underwent red 572 
blood cell lysis (BD Pharm Lyse) before incubation in alpha-MEM + 10% StasisTM FBS (Gemini 573 
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Bio-Products) + MitoTrackerTM Red CMXRos (Invitrogen) for 30 minutes to stain for membrane 574 
potential of mitochondria.  Cells were then stained for viability (Invitrogen) and surface stained 575 
to distinguish erythroid progenitor populations by CD34 (581; Biolegend), CD235a (HIR2; BD 576 
Pharmingen), CD71 (L01.1; BD Pharmingen) and CD45 (D058-1283; BD Pharmingen).  All 577 
samples were acquired on an LSR II (BD) and analyzed with FlowJo Software (Treestar, Inc.).  578 
Gating strategies are provided in applicable figures.   579 
For the multiplex assays, all samples and supernatants were stored at -80°C from time of 580 
necropsy until time of assay. Five representative granuloma supernatants were randomly 581 
selected from each animal using JMP Pro v12 (SAS Institute Inc.).  Supernatants were thawed 582 
and filtered with a 0.22uM syringe filter to remove infectious bacteria and debris, then kept on 583 
ice throughout the assay. For BAL samples, supernatants were concentrated using regenerated 584 
cellulose centrifugal filter tubes (3,000 NMWL, Millipore Sigma) to a final 10X concentration 585 
(5mL to 0.5mL).  Both granuloma and BAL supernatants were evaluated with a ProcartaPlex 586 
multiplex immunoassay (Invitrogen) that assesses thirty cytokines and chemokines specific for 587 
NHPs.  We followed the manufacturer’s protocol with one modification in which we diluted the 588 
standard out an extra dilution to increase the range of detection.  Results were analyzed by a 589 
BioPlex reader (BioRad).   590 
 591 
Histopathology and immunofluorescence 592 
Mice.  Lung tissues were fixed in 10% buffered formalin and embedded in paraffin. Five 593 
micrometer-thick sections were stained with hematoxylin and eosin (H&E). Tissue staining was 594 
done by the Diabetes and Endocrinology Research Center histopathology core facility at the 595 
University of Massachusetts Medical School or immunology core facility of Albany medical 596 
college, NY. Brightfield images were acquired in Abaxis VETSCAN HD microscope.  597 
Paraffin embedded lung tissue sections were cut at 5 μm thickness, mounted on ultraclean glass 598 
slides covered in silane, deparaffinized, then dehydrated and rehydrated using the following 599 
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steps: Ethanol solutions (30, 50, 70, 90, 95 and 100 % for 3 min each), xylenes (2 different 600 
solutions for 10 min each) and ethanol solutions (100, 95, 90, 70, 50 and 30 for 3 min each). The 601 
slides were washed once in Tris buffer saline (TBS) for 5 min. Slices were subjected to antigen 602 
retrieval by boiling in sodium citrate buffer at pH=6.0 for 20 min and incubated in 0.1% Triton-X 603 
100 for 5 min.  Slices were removed and allowed to equilibrate to room temperature for at least 604 
20 min, and rinsed with distilled water. Tissue sections were blocked (blocking solution; 0.5 M 605 
EDTA, 1% BSA, in PBS) and incubated overnight in primary antibodies against the proteins 606 
related to our studies. Sections were stained for nuclei (DAPI, blue staining), anti-mouse CD3e 607 
(cat.no. ab16669, green staining), anti-mouse Ly-6G (clone 1A8, cat. no. 127602) to identify 608 
neutrophil granulocytes (Cy3, red staining).  As controls, pre-immune serum and isotype matched 609 
controls were used. After incubation, the tissues were washed several times with sterile TBS at 610 
room temperature and incubated in the respective secondary antibodies (anti-rabbit conjugated 611 
to Alexa-488, anti-rat conjugated to Cy3) for at least 2h at room temperature. Tissue sections 612 
were mounted using Prolong Gold Antifade reagent (Invitrogen, grand Island, NY) with DAPI, and 613 
the tissue sections were examined in ECHO Revolve 4 microscope. Isotype matched control 614 
antibodies were used for checking antibody specificity.  615 
Macaques.  As previously described, samples acquired at necropsy were formalin fixed, 616 
paraffin embedded, cut into ~5µm serial sections and stained with H&E (34).  A study-blinded 617 
veterinary pathologist assessed and characterized each granuloma, indicating size, type, 618 
distribution and cellular composition.  Sterna for bone marrow analysis were excised and 619 
formalin fixed then transected longitudinally into 1 to 2 sternebral unites and placed in Cal-Ex 620 
Hydrochloric acid decalcification solution for 2-4 hours.  Upon removal, specimens were washed 621 
and trimmed to test for adequate mineral removal, then submitted for routine tissue processing 622 
with other tissue specimens as described above.  623 
  624 
Statistical Analysis 625 
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Mouse studies: Equal variance between samples was assessed by Brown-Forsythe test. 626 
Experiments in which variances were equivalent were analyzed by one-way ANOVA with 627 
Sidak’s multiple comparisons test.  Those with unequal variances were analyzed by Welch 628 
ANOVA and Dunnett’s multiple comparisons test. P values < 0.05 was considered significant.  629 
Macaque studies: Nonparametric U tests (Mann-Whitney) were performed for two-group 630 
comparisons and Kruskal-Wallis tests were performed for three-group comparisons as indicated 631 
on data sets with non-normal distributions. Wilcoxon signed rank tests were performed for 632 
matched pairs. Fisher’s exact test was run on any categorical data. P values < 0.05 were 633 
considered significant. Total lung FDG activity was log10-transformed.  A two-way ANOVA was utilized 634 
to test whether treatment or time (or an interaction between these factors) had an effect on total 635 
lung inflammation.  Dunnett’s multiple comparison tests were then used to compare each time 636 
point to pre-drug treatment within each treatment group. Statistical analyses were performed in 637 
GraphPad Prism 8 (GraphPad Software, San Diego, CA).  A regression equation created from 638 
control animals from previous studies was used to create a 95% prediction interval for total 639 
thoracic bacterial burden using total lung FDG activity on the scan just before drug treatment 640 
(20). The lower and upper bounds and the mean of this prediction interval were subtracted from 641 
each animal’s total CFU to estimate change in CFU over the course drug treatment.  All 642 
statistical analyses are referenced in the corresponding figure legends.   643 
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Figure 1. IL-1 inhibition in susceptible mice reduces inflammation with no effect on lung 746 
bacterial burden.     747 
Wild type C57BL/6 and Nos2-/- mice were infected with Mtb Erdman for 2 weeks, and treated 748 
with anti-IL-1R1 (aIL-1R1) or IL-1R1-antagonist (IL-1Rn) for the subsequent 2 weeks. (A) Lung 749 
neutrophil (PMN) infiltration was quantified by flow cytometry; (B) Weight loss and (C) CFU in 750 
lung and (D) spleen are shown. Data shown (mean ± SD) are representative of two independent 751 
experiments. One-way ANOVA with Sidak’s multiple comparisons-test was used. N=4 mice per 752 
treatment cohorts. (E) Histopathology analysis of a single lung lobe from WT or Nos2-/- mice 753 
was performed by Hematoxylin-eosin (H&E) staining. 754 
 755 
 756 
Figure 2. IL-1R1 blockade combined with Linezolid ameliorates TB disease. 757 
(A-D) C3HeB/FeJ mice were infected with Mtb Erdman for 4 weeks and treated with linezolid 758 
(LZD) and/or anti-IL-1R1 (aIL-1R1) for the following 18 days. (A) Lung neutrophils were 759 
quantified by flow cytometry; (B) Percent change in body weight is shown and (C) Bacterial 760 
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burden in the lung and (D) spleen were quantified as CFU. Data shown (Mean ± SD) are 761 
representative of two independent experiments. Welch ANOVA with Dunnett’s post-test was 762 
used to calculate statistical significance where each treatment group was compared to the 763 
vehicle as control group. N=3-5 mice per treatment group. (E-G) C3HeB/FeJ mice were infected 764 
with M. tb Erdman for 8 weeks and treated with linezolid (LZD) and/or an inhibitor of the NLRP3 765 
inflammasome (MCC950) for the following 21 days. (E) Lung neutrophils were quantified by flow 766 
cytometry. (F) Bacterial burden in the lung was quantified by CFU. Data shown (Mean ± SD) are 767 
from one experiment. One-way ANOVA with Tukey’s multiple comparison test was used to 768 
calculate the p-value. N=4-5 mice/group. (G)  Representative immunofluorescence images of 769 
the lungs from different treatment groups. Cell nuclei stained with DAPI (blue), T-cells stained 770 
with anti-mouse CD3e (green) and neutrophils stained with anti-mouse Ly-6G (red). 771 
 772 
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Figure 3.  Erythropoiesis associated with LZD treatment was partially relieved after IL-773 
1R1 blockade. 774 
C3HeB/FeJ mice were infected with Mtb Erdman for 4 weeks, and treated with LZD either alone 775 
or in combination with anti-IL-1R1 antibody for the subsequent 18 days. (A) Gating strategy for 776 
detecting erythroid progenitors is shown. Erythroid progenitors in the spleen (B-C) and bone 777 
marrow (D-E) were quantified by flow cytometry as described in Materials and Methods. 778 
Representative flow cytometry plots and percent changes in the early erythroid progenitors (Pro-779 
Ery, EryA, EryB) among different treatment groups are shown. Data shown (Mean ± SD) are 780 
from two independent experiments. One-way ANOVA with Dunnett’s post-test was applied to 781 
calculate the p-value by comparing the mean of each group with that of LZD treated group. 782 
N=3-5 mice per group.  783 
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 784 
Figure 4.  HDT reduces granuloma inflammation by PET/CT in macaques 785 
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Cynomolgus macaques were infected with M. tb Erdman for approximately 4 months (see 786 
Supplementary Table 1) and randomized to treatment with LZD or LZD+IL-1Rn for an additional 787 
4 weeks.  PET/CT scans were performed pre-treatment, 2 and 4 weeks post-treatment with 4 788 
week scans as the last prior to necropsy.  (A) 3-D renderings of PET/CT scans from pre-789 
treatment and 4 weeks post-treatment are depicted, with “best” and “worst” of each group 790 
referring to TB disease prior to drug administration.  (B) Total lung FDG activity of each 791 
macaque throughout treatment with LZD (left) or LZD+IL-1Rn (right).  Two-way ANOVA with 792 
Dunnett’s adjusted p-values are reported. (C) Individual granulomas were identified pre-793 
treatment and tracked post-treatment by PET/CT.  Change in size (by CT) was determined for 794 
granulomas from each animal; the left graph is compiled granulomas from each animal in the 795 
indicated treatment groups while the right depicts individual animals.  (D) Standard uptake value 796 
(SUVR) of 18F-FDG was calculated for each granuloma, representing inflammation.  Change in 797 
SUVR of all granulomas in each groupis depicted on the left, while change in SUVR of 798 
granulomas from each individual animal are on the right.  For (C) and (D), each data point is 799 
representative of one granuloma and the bar represents the median.  Mann-Whitney tests 800 
determined p values for (C) and (D), with p<0.05 considered significant.    801 
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 802 
Figure 5.  Addition of IL-1Rn does not enhance efficacy of LZD for bacterial killing 803 
Bacterial burden is shown after 4 weeks of LZD (blue) or LZD+IL-1Rn (red) treatment.  (A) Total 804 
thoracic (lung + lymph nodes) and lung CFU; each data point represents one macaque. Total 805 
thoracic CFU from 3 similarly infected untreated historical control macaques (black) are included 806 
as reference for untreated CFU at this time point, but excluded from statistical analysis.  (B) The 807 
percent of all lung granulomas that were CFU+ per monkey. (C) CFU of all thoracic lymph 808 
nodes with data points representing CFU from one macaque.  CFU+ lymph nodes show the 809 
CFU from each thoracic lymph node in any animal that was Mtb+.  For (A) and (B), p values 810 
were determined by Mann-Whitney test. (C) PET/CT scans from pre-treatment were used to 811 
model predicted CFU prior to HDT initiation and compared to actual CFU determined at time of 812 
necropsy.  The predicted change in CFU was determined by: Actual total thoracic CFU post-813 
treatment– Predicted total thoracic CFU interval (predicted from pre-drug-treatment scan).  Bars 814 
represent mean of prediction intervals and error whiskers represent the lower and upper bounds 815 
of the difference between final total CFU and predicted CFU prior to drug treatment.  816 
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 817 
Figure 6. Linezolid-associated bone marrow suppression was not observed in macaques 818 
Bone marrow was acquired from the sternum of all macaques at necropsy after 4 weeks LZD or 819 
LZD+IL-1Rn.  A portion was used for flow cytometric analysis of erythroid progenitor populations 820 
and the rest for histopathology analysis.  (A) A schematic of erythropoiesis indicating the stage 821 
of differentiation and corresponding expression levels of phenotyping markers (CD235 and 822 
CD71) and progenitor ratios (1:2:4:8).  Included is the gating strategy to identify progenitor 823 
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populations and an example of MitoTracker staining. (B) The ProE:EryC ratio (left) of each 824 
animal, including untreated TB only macaques (black) from other ongoing unpublished studies.  825 
A single uninfected animal (open circle) is shown as reference, the dotted line indicates the 826 
homeostatic ratio of 1:8.  MitoTracker MFI (right) is shown for each macaque per treatment 827 
group. Kruskal-Wallis test was performed to compare the three groups (excluding uninfected 828 
macaque) and p values are shown in the graphs. (C) Representative H&E images from sternal 829 
bone marrow acquired at necropsy, 20x (left) and 40x (right) are shown.   830 
 831 
Figure 7.  HDT reduces inflammatory signatures in BAL  832 
Bronchoalveolar lavages (BAL) were acquired pre-treatment and 3 weeks post-treatment with 833 
LZD (blue) or LZD+IL-1Rn (red).  (A) Cells were analyzed by flow cytometry to determine 834 
frequency changes in CD4 T cells (CD3+CD4+), CD8 T cells (CD3+CD8+), macrophages 835 
(CD11b+CD206+) and neutrophils (CD11b+Calprotectin+).  Wilcoxon signed rank test was 836 
performed to determine differences before and after drug treatment, regardless of group (LZD 837 
and LZD+IL-1Rn combined).  (B) BAL fluid was concentrated 10X and assessed by multiplex 838 
assay for changes in inflammatory cytokines and chemokines for a random subset of samples 839 
(n=3 per treatment group).  Wilcoxon signed rank test was performed to determine differences 840 
before and after drug treatment, regardless of group (LZD and LZD+IL-1Rn combined).   841 
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 842 
Figure 8.  Inflammation modulation by HDT influences granuloma resolution 843 
Randomly selected granulomas (n=5 per macaque, n=25 per treatment group) were subjected 844 
to multiplex analysis to determine differences between treatment groups (colors indicate lesions 845 
from a single animal).  p values shown determined by Mann-Whitney test.  (B) Granulomas from 846 
LZD (n=57) and LZD+IL-1Rn (n=45) were examined by a pathologist (EK) and categorized.  We 847 
compared fibrotic (green) vs non-fibrotic (light gray) (left) and necrotizing (red) vs non-848 
.CC-BY 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/792390doi: bioRxiv preprint first posted online Oct. 3, 2019; 
 41 
necrotizing (blue) granuloma frequencies.  Frequencies represent the percentage of all 849 
granulomas within treatment groups.  Fisher’s exact test p-values are reported.   850 
 851 
Supporting information 852 
Supplementary Table 1.  List of macaques for study and PET/hot values. 853 
Provided are details regarding macaques utilized for this study.  DPI = days post infection.  854 
 855 
S1 Fig. Inhibiting inflammasome signaling does not interfere with LZD efficacy. 856 
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(A) Wild type C57BL/6 and Caspase-1/11-/- mice were infected with M. tb Erdman for 2 weeks, 857 
and treated with linezolid for the subsequent 2 weeks. (A) Lung neutrophil (PMN) infiltration was 858 
quantified by flow cytometry. (B) CFU in the lung are shown. Data shown (Mean ± SD) are 859 
representative of two independent experiments.  (C) WT and Nlrp3-/- mice were infected with M. 860 
tb Erdman for 2 weeks and treated with linezolid for the following two weeks. (C) Lung 861 
neutrophils were quantified by flow cytometry. (D) Bacterial burden in the lung were quantified 862 
as CFU. Data shown (Mean ± SD) are from one experiment. One-way ANOVA with Sidak’s 863 
multiple comparison test was used to calculate the indicated p-values. N=3-5 mice used for 864 
each treatment group. 865 
 866 
 867 
S2 Fig.  Linezolid pharmacokinetic analyses and Experimental plan for HDT in macaques 868 
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(A) Plasma concentration time profiles of cynomolgus macaques receiving 20mg/kg or 40mg/kg 869 
linezolid.  Average plasma concentrations were plotted on Day 1 and Day 5 post-dose (n=3) (B) 870 
Experimental timeline of macaque study.   871 
 872 
S3 Fig.  Complete blood counts and erythrocyte sedimentation rate for macaques 873 
undergoing HDT  874 
Complete blood counts (CBCs) were taken through the study to assess anemia caused by 875 
linezolid or Mtb infection.  The CBC values (top) show true values for each macaque in LZD 876 
(blue) or LZD+IL-1Rn (red) treatment groups.  Due to variability in animal size and age, we 877 
normalized CBC values to the preinfection time point for each animal (middle graphs).  These 878 
data indicate the relative change over the course of HDT.  ESR (bottom) is a non-specific 879 
measure of inflammation, LZD (blue) and LZD+IL-1Rn (red) treated macaques are depicted. 880 
 881 
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